Acetylcholinesterase inhibitors and nanoparticles on Alzheimer’s disease: a review
Source abstract
Abstract
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease clinically characterized by progressive loss of memory, impairment cognitive function, and neuropsychiatric and behavior dysfunction. The molecular pathology of the disease is characterized with extracellular accumulation of amyloid β plaques and neurofibrillary tangles composed of hyperphosphorylated Tau. Even with crescent number of AD patients worldwide, the current treatment approved does not alter the course of the disease but rather controls the symptoms. In addition to this, also present poor solubility and low bioavailability. Therefore, several studies have been exploring new delivery systems to efficiently deliver those drugs and enhance biological activity. Among them, nanoparticulated systems have demonstrated great potential as a drug delivery system in neurodegenerative disease. In this review, we will reflect on the current progress of nanoparticulated systems with an overall particle size ranging from 2 up to 200 nm and potential to deliver AD drugs for AD treatment.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cholinesterase and Neurodegenerative Diseases · Alzheimer's disease research and treatments · Computational Drug Discovery Methods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (83)
Show source-provided references
1. Alonso MJ, Couvreur P (2012) Chapter 1. historical view of the design and development of nanocarriers for overcoming biological barriers. In: nanostructured biomaterials for overcoming biological barriers. The Royal Society of Chemistry, pp 3–36
2. Bales KR, Verina T, Dodel RC, du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17:263–264. https://doi.org/10.1038/ng1197-26310.1038/ng1197-263 ↗
3. Bales KR, Verina T, Cummins DJ, du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 96:15233–15238. https://doi.org/10.1073/pnas.96.26.1523310.1073/pnas.96.26.15233 ↗
4. Battaglia L, Gallarate M (2012) Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 9:497–508. https://doi.org/10.1517/17425247.2012.67327810.1517/17425247.2012.673278 ↗
5. Baysal I, Ucar G, Gultekinoglu M, Ulubayram K, Yabanoglu-Ciftci S (2017) Donepezil loaded PLGA-b-PEG nanoparticles: their ability to induce destabilization of amyloid fibrils and to cross blood brain barrier in vitro. J Neural Transm 124:33–45. https://doi.org/10.1007/s00702-016-1527-410.1007/s00702-016-1527-4 ↗
6. Benítez-Martínez S, Caballero-Díaz E, Valcárcel M (2016) Development of a biosensing system for tacrine based on nitrogen-doped graphene quantum dots and acetylcholinesterase. Analyst 141:2688–2695. https://doi.org/10.1039/c6an00357e10.1039/c6an00357e ↗
7. Bhavna B, Shadab M, Ali M et al (2014) Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm 40:278–287. https://doi.org/10.3109/03639045.2012.75813010.3109/03639045.2012.758130 ↗
8. Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD001190.pub310.1002/14651858.CD001190.pub3 ↗
9. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368:387–403. https://doi.org/10.1016/S0140-6736(06)69113-710.1016/S0140-6736(06)69113-7 ↗
10. Briggs R, Kennelly SP, O’Neill D (2016) Drug treatments in Alzheimer’s disease. Clin Med (Northfield Il) 16:247–253. https://doi.org/10.7861/clinmedicine.16-3-24710.7861/clinmedicine.16-3-247 ↗
11. Bryson HM, Benfield P (1997) Donepezil. Drugs Aging 10:234–239. https://doi.org/10.2165/00002512-199710030-0000710.2165/00002512-199710030-00007 ↗
12. Butterfield DA, Halliwell B (2019) Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci 20:148–160. https://doi.org/10.1038/s41583-019-0132-610.1038/s41583-019-0132-6 ↗
13. Cole L, Kramer PR (2016) Alzheimer’s disease. In: Human physiology. Elsevier, Biochemistry and Basic Medicine, pp 215–217
14. Corace G, Angeloni C, Malaguti M, Hrelia S, Stein PC, Brandl M, Gotti R, Luppi B (2014) Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res 24:323–335. https://doi.org/10.3109/08982104.2014.89936910.3109/08982104.2014.899369 ↗
15. Craparo EF, Pitarresi G, Bondi ML et al (2008) A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci 8:247–259. https://doi.org/10.1002/mabi.20070016510.1002/mabi.200700165 ↗
16. Crismon ML (1994) Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother 28:744–751. https://doi.org/10.1177/10600280940280061210.1177/106002809402800612 ↗
17. D’souza AA, Shegokar R (2016) Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv 13:1257–1275. https://doi.org/10.1080/17425247.2016.118248510.1080/17425247.2016.1182485 ↗
18. Desai AK, Grossberg GT (2005) Rivastigmine for Alzheimer’s disease. Expert Rev Neurother 5:563–580. https://doi.org/10.1586/14737175.5.5.56310.1586/14737175.5.5.563 ↗
19. Dinesh Raja A, Mohambed M, Joji S et al (2012) Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil. Iran J Pharm Sci 8:155–164
20. Enz A, Boddeke H, Gray J, Spiegel R (1991) Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann N Y Acad Sci 640:272–275. https://doi.org/10.1111/j.1749-6632.1991.tb00232.x10.1111/j.1749-6632.1991.tb00232.x ↗
21. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155–170. https://doi.org/10.1016/j.brainresbull.2018.10.00910.1016/j.brainresbull.2018.10.009 ↗
22. Eslami M, Nikkhah SJ, Hashemianzadeh SM, Sajadi SAS (2016) The compatibility of tacrine molecule with poly(n-butylcyanoacrylate) and chitosan as efficient carriers for drug delivery: a molecular dynamics study. Eur J Pharm Sci 82:79–85. https://doi.org/10.1016/j.ejps.2015.11.01410.1016/j.ejps.2015.11.014 ↗
23. Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni J, Ali J (2012) Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 47:6–15. https://doi.org/10.1016/j.ejps.2012.04.01310.1016/j.ejps.2012.04.013 ↗
24. Fornaguera C, Feiner-Gracia N, Calderó G, García-Celma MJ, Solans C (2015) Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases. Nanoscale 7:12076–12084. https://doi.org/10.1039/c5nr03474d10.1039/c5nr03474d ↗
25. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJC (1989) Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 46:634–641. https://doi.org/10.1038/clpt.1989.19910.1038/clpt.1989.199 ↗
26. Fulton B, Benfield P (1996) Galanthamine. Drugs Aging 9:60–65. https://doi.org/10.2165/00002512-199609010-0000610.2165/00002512-199609010-00006 ↗
27. Galimberti D, Scarpini E (2012) Progress in Alzheimer’s disease. J Neurol 259:201–211. https://doi.org/10.1007/s00415-011-6145-310.1007/s00415-011-6145-3 ↗
28. Grenha A (2012) Chitosan nanoparticles: a survey of preparation methods. J Drug Target 20:291–300. https://doi.org/10.3109/1061186X.2011.65412110.3109/1061186X.2011.654121 ↗
29. Hansen DV, Hanson JE, Sheng M (2018) Microglia in Alzheimer’s disease. J Cell Biol 217:459–472. https://doi.org/10.1083/jcb.20170906910.1083/jcb.201709069 ↗
30. Hardy J, Higgins G (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science (80-) 256:184–185. https://doi.org/10.1126/science.156606710.1126/science.1566067 ↗
31. Hassani S, Laouini A, Fessi H, Charcosset C (2015) Preparation of chitosan-TPP nanoparticles using microengineered membranes - effect of parameters and encapsulation of tacrine. Colloids Surfaces A Physicochem Eng Asp 482:34–43. https://doi.org/10.1016/j.colsurfa.2015.04.00610.1016/j.colsurfa.2015.04.006 ↗
32. Hassanzadeh G, Fallahi Z, Khanmohammadi M, Elmizadeh H (2016) Effect of magnetic tacrine-loaded chitosan nanoparticles on spatial learning, memory, amyloid precursor protein and seladin-1 expression in the hippocampus of streptozotocin-exposed rats. Int Clin Neurosci J 3:25–31. https://doi.org/10.22037/icnj.v3i1.1235810.22037/icnj.v3i1.12358 ↗
33. Heneka MT, Carson MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405. https://doi.org/10.1016/S1474-4422(15)70016-510.1016/S1474-4422(15)70016-5 ↗
34. Ismail MF, Elmeshad AN, Salem NAH (2013) Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease. Int J Nanomedicine 8:393–406. https://doi.org/10.2147/IJN.S3923210.2147/IJN.S39232 ↗
35. Jain KK (2000) Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 9:1397–1406. https://doi.org/10.1517/13543784.9.6.139710.1517/13543784.9.6.1397 ↗
36. Jarvis B, Figgitt DP (2003) Memantine. Drugs Aging 20:465–476. https://doi.org/10.2165/00002512-200320060-0000510.2165/00002512-200320060-00005 ↗
37. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR (2008) Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 22:116–124. https://doi.org/10.1097/WAD.0b013e318157205b10.1097/WAD.0b013e318157205b ↗
38. Joshi SA, Chavhan SS, Sawant KK (2010) Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76:189–199. https://doi.org/10.1016/j.ejpb.2010.07.00710.1016/j.ejpb.2010.07.007 ↗
39. Karimzadeh M, Rashidi L, Ganji F (2017) Mesoporous silica nanoparticles for efficient rivastigmine hydrogen tartrate delivery into SY5Y cells. Drug Dev Ind Pharm 43:628–636. https://doi.org/10.1080/03639045.2016.127566810.1080/03639045.2016.1275668 ↗
40. Kawashima K, Sato A, Yoshizawa M, et al (1994) Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 350:523–528. https://doi.org/10.1007/BF0017302210.1007/BF00173022 ↗
41. Krishna KV, Wadhwa G, Alexander A, Kanojia N, Saha RN, Kukreti R, Singhvi G, Dubey SK (2019) Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chem Neurosci 10:4124–4135. https://doi.org/10.1021/acschemneuro.9b0034310.1021/acschemneuro.9b00343 ↗
42. Lane CA, Hardy J, Schott JM (2018) Alzheimer’s disease. Eur J Neurol 25:59–70. https://doi.org/10.1111/ene.1343910.1111/ene.13439 ↗
43. Laserra S, Basit A, Sozio P, Marinelli L, Fornasari E, Cacciatore I, Ciulla M, Türkez H, Geyikoglu F, di Stefano A (2015) Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization. Int J Pharm 485:183–191. https://doi.org/10.1016/j.ijpharm.2015.03.00110.1016/j.ijpharm.2015.03.001 ↗
44. Lee J-H, Park H-KC TG (1999) Development of oral drug delivery system using floating microspheres. J Microencapsul 16:715–729. https://doi.org/10.1080/02652049928866310.1080/026520499288663 ↗
45. Luppi B, Bigucci F, Corace G, Delucca A, Cerchiara T, Sorrenti M, Catenacci L, di Pietra AM, Zecchi V (2011) Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur J Pharm Sci 44:559–565. https://doi.org/10.1016/j.ejps.2011.10.00210.1016/j.ejps.2011.10.002 ↗
46. Madden S, Spaldin V, Park BK (1995) Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 28:449–457. https://doi.org/10.2165/00003088-199528060-0000310.2165/00003088-199528060-00003 ↗
47. Malekpour-Galogahi F, Hatamian-Zarmi A, Ganji F, Ebrahimi-Hosseinzadeh B, Nojoki F, Sahraeian R, Mokhtari-Hosseini ZB (2018) Preparation and optimization of rivastigmine-loaded tocopherol succinate-based solid lipid nanoparticles. J Liposome Res 28:226–235. https://doi.org/10.1080/08982104.2017.134914310.1080/08982104.2017.1349143 ↗
48. Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, Iwata N (2018) The efficacy and safety of memantine for the treatment of Alzheimer’s disease. Expert Opin Drug Saf 17:1053–1061. https://doi.org/10.1080/14740338.2018.152487010.1080/14740338.2018.1524870 ↗
49. Mendes IT, Ruela ALM, Carvalho FC, Freitas JTJ, Bonfilio R, Pereira GR (2019) Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B: Biointerfaces 177:274–281. https://doi.org/10.1016/j.colsurfb.2019.02.00710.1016/j.colsurfb.2019.02.007 ↗
50. Misra S, Chopra K, Sinha VR, Medhi B (2016a) Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv 23:1434–1443. https://doi.org/10.3109/10717544.2015.108995610.3109/10717544.2015.1089956 ↗
51. Misra S, Chopra K, Saikia UN, Sinha VR, Sehgal R, Modi M, Medhi B (2016b) Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer’s disease. Regen Med 11:629–646. https://doi.org/10.2217/rme-2016-003210.2217/rme-2016-0032 ↗
52. Mufamadi MS, Choonara YE, Kumar P, Modi G, Naidoo D, van Vuuren S, Ndesendo VMK, Toit LC, Iyuke SE, Pillay V (2013) Ligand-functionalized nanoliposomes for targeted delivery of galantamine. Int J Pharm 448:267–281. https://doi.org/10.1016/j.ijpharm.2013.03.03710.1016/j.ijpharm.2013.03.037 ↗
53. Nagpal K, Singh SK, Mishra DN (2013) Optimization of brain targeted chitosan nanoparticles of rivastigmine for improved efficacy and safety. Int J Biol Macromol 59:72–83. https://doi.org/10.1016/j.ijbiomac.2013.04.02410.1016/j.ijbiomac.2013.04.024 ↗
54. Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet 52:225–241. https://doi.org/10.1007/s40262-013-0038-910.1007/s40262-013-0038-9 ↗
55. Nordberg A, Svensson A-L (1998) Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Drug Saf 19:465–480. https://doi.org/10.2165/00002018-199819060-0000410.2165/00002018-199819060-00004 ↗
56. Ohnishi A, Mihara M, Kamakura H, Tomono Y, Hasegawa J, Yamazaki K, Morishita N, Tanaka T (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33:1086–1091. https://doi.org/10.1002/j.1552-4604.1993.tb01945.x10.1002/j.1552-4604.1993.tb01945.x ↗
57. Owens DE, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102. https://doi.org/10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
58. Pagar K, Vavia P (2013) Rivastigmine-loaded L-lactide-depsipeptide polymeric nanoparticles: decisive formulation variable optimization. Sci Pharm 81:865–885. https://doi.org/10.3797/scipharm.1211-2010.3797/scipharm.1211-20 ↗
59. Palle S, Neerati P (2017) Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases. Pharmacol Rep 69:365–370. https://doi.org/10.1016/j.pharep.2016.12.00210.1016/j.pharep.2016.12.002 ↗
60. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation I. methods for preparation of drug-loaded polymeric nanoparticles. Nanomed Nanotechnol Biol Med 2:8–21. https://doi.org/10.1016/j.nano.2005.12.00310.1016/j.nano.2005.12.003 ↗
61. Querfurth HW, LaFerla FM (2010) Mechanisms of disease Alzheimer’s disease. N Engl J Med 362:329–34410.1056/NEJMra0909142 ↗
62. Radwan RR, Ghaffar AMA, Ali HE (2019) Gamma radiation preparation of chitosan nanoparticles for controlled delivery of memantine. https://doi.org/10.1177/088532821989007110.1177/0885328219890071 ↗
63. Rainer M (1997) Galanthamine in Alzheimer’s disease. A new alternative to tacrine? CNS Drugs 7:89–97. https://doi.org/10.2165/00023210-199707020-0000110.2165/00023210-199707020-00001 ↗
64. Razay G, Wilcock GK (2008) Galantamine in Alzheimer’s disease. Expert Rev Neurother 8:9–17. https://doi.org/10.1586/14737175.8.1.910.1586/14737175.8.1.9 ↗
65. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348:1333–1341. https://doi.org/10.1056/NEJMoa01312810.1056/NEJMoa013128 ↗
66. Saladini B, Bigucci F, Cerchiara T, Gallucci MC, Luppi B (2013) Microparticles based on chitosan/pectin polyelectrolyte complexes for nasal delivery of tacrine hydrochloride. Drug Deliv Transl Res 3:33–41. https://doi.org/10.1007/s13346-012-0086-y10.1007/s13346-012-0086-y ↗
67. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M (2017) Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: development, characterization, ex vivo permeation and cellular studies. Colloids Surf B: Biointerfaces 159:629–638. https://doi.org/10.1016/j.colsurfb.2017.08.03110.1016/j.colsurfb.2017.08.031 ↗
68. Sánchez-López E, Ettcheto M, Egea MA, Espina M, Cano A, Calpena AC, Camins A, Carmona N, Silva AM, Souto EB, García ML (2018) Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization. J Nanobiotechnol 16:1–16. https://doi.org/10.1186/s12951-018-0356-z10.1186/s12951-018-0356-z ↗
69. Santello M, Toni N, Volterra A (2019) Astrocyte function from information processing to cognition and cognitive impairment. Nat Neurosci 22:154–166. https://doi.org/10.1038/s41593-018-0325-810.1038/s41593-018-0325-8 ↗
70. Sathesh Kumar S, Felix Joe V (2017) Pharmacokinetics of tacrine loaded MPEG-PCL polymeric nanoparticles. Res J Pharm Technol 10:135–140. https://doi.org/10.5958/0974-360X.2017.00030.010.5958/0974-360X.2017.00030.0 ↗
71. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. https://doi.org/10.15252/emmm.20160621010.15252/emmm.201606210 ↗
72. Shah B, Khunt D, Bhatt H, Misra M, Padh H (2015) Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci 78:54–66. https://doi.org/10.1016/j.ejps.2015.07.00210.1016/j.ejps.2015.07.002 ↗
73. Sharon, Friedhoff LR (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dement Geriatr Cogn Disord 7:293–303. https://doi.org/10.1159/00010689510.1159/000106895 ↗
74. Silva S, Marto J, Gonçalves L, et al (2020) Formulation, characterization and evaluation against sh-sy5y cells of new tacrine and tacrine-map loaded with lipid nanoparticles. Nanomaterials 10:. https://doi.org/10.3390/nano1010208910.3390/nano10102089 ↗
75. Singh R, Lillard JW (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215–223. https://doi.org/10.1016/j.yexmp.2008.12.00410.1016/j.yexmp.2008.12.004 ↗
76. Sozio P, Cerasa LS, Laserra S, Cacciatore I, Cornacchia C, di Filippo ES, Fulle S, Fontana A, di Crescenzo A, Grilli M, Marchi M, di Stefano A (2013) Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer’s disease. Eur J Pharm Sci 49:187–198. https://doi.org/10.1016/j.ejps.2013.02.01310.1016/j.ejps.2013.02.013 ↗
77. Tamilselvan N, Raghavan CV (2015) Formulation and characterization of anti-Alzheimer’s drug loaded chitosan nanoparticles and its in vitro biological evaluation. J Young Pharm 7:28–35. https://doi.org/10.5530/jyp.2015.1.610.5530/jyp.2015.1.6 ↗
78. Wenk GL, Quack G, Moebius HJ, Danysz W (2000) No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 66:1079–1083. https://doi.org/10.1016/S0024-3205(00)00411-210.1016/S0024-3205(00)00411-2 ↗
79. Wilson B, Samanta MK, Santhi K et al (2008a) Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 70:75–84. https://doi.org/10.1016/j.ejpb.2008.03.00910.1016/j.ejpb.2008.03.009 ↗
80. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B (2008b) Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res 1200:159–168. https://doi.org/10.1016/j.brainres.2008.01.03910.1016/j.brainres.2008.01.039 ↗
81. Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B (2010) Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomed Nanotechnol Biol Med 6:144–152. https://doi.org/10.1016/j.nano.2009.04.00110.1016/j.nano.2009.04.001 ↗
82. Wilson B, Samanta MK, Muthu MS, Vinothapooshan G (2011) Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer’s disease. Ther Deliv 2:599–609. https://doi.org/10.4155/tde.11.2110.4155/tde.11.21 ↗
83. Yasir M, Sara UVS, Chauhan I, Gaur PK, Singh AP, Puri DA (2018) Solid lipid nanoparticles for nose to brain delivery of donepezil: formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol 46:1838–1851. https://doi.org/10.1080/21691401.2017.139487210.1080/21691401.2017.1394872 ↗